To the Editor: Dr Kim and colleagues1 found elevated serum osteopontin levels in patients
with ovarian carcinoma. While the authors' approach has high sensitivity,
the nonspecific nature of osteopontin expression in many diseases limits the
potential clinical application of serum osteopontin as a unique biomarker
for ovarian cancer.
Test specificity is central to any biomarker or screening program. Osteopontin
may be expressed in many inflammatory and noninflammatory diseases including
cancers of varied tissue origin.2,3
Although a variety of cell types express osteopontin, macrophages are a major
source.2 Even in carcinoma, there is evidence
that infiltrating macrophages rather than tumor cells are the principal source
of osteopontin.3 Prior investigations have
shown very high levels of osteopontin in hemodialysis patients with arterial
atherosclerosis and in patients with gram-negative sepsis.4
These studies suggest that assays of total serum osteopontin alone will lack
sufficient specificity to be a clinically applicable cancer biomarker.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.